KLOW peptide dosage: what the component research measured

In plain English

KLOW peptide dosage cannot be summarized as a single number. The reason is structural: KLOW is a four-component blend, and each component has been studied at different doses in different species by different routes — none of them as part of the blend itself. The best-known starting point is the composition of the canonical research vial: 80 mg total, split as GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. No human dosing study exists for the blend. What this page provides is the composition data, the per-component doses studied in preclinical models, the half-life picture for each arm, and a plain statement of what the pharmacokinetic mismatch means for anyone interpreting the literature. This is research context, not a recommendation. KLOW peptide dosage and frequency for humans have never been formally studied.

KLOW peptide dosage: the canonical vial composition

The most widely listed research-vial composition across independent compounders:

• GHK-Cu: 50 mg (62.5% of total, mass-dominant)
• BPC-157: 10 mg
• TB-500: 10 mg
• KPV: 10 mg
• Total: 80 mg, lyophilized, reconstituted with bacteriostatic water for laboratory handling

This 50/10/10/10 ratio is not derived from any combination study or dose-optimization trial. No FDA-approved formulation exists; no pharmacopeial KLOW specification exists. The ratio reflects a convention adopted by peptide-compounding researchers, not a validated therapeutic ratio.

The lyophilized blend, once reconstituted, is typically refrigerated. Copper(II) in GHK-Cu can participate in redox chemistry; co-dissolving it with three other peptides in one vial raises a theoretical compatibility and oxidation question that has not been formally characterized for this mixture.

KLOW dosage: component-level doses from preclinical models

Because no controlled combination study exists, the preclinical evidence for each arm comes from single-component studies. Doses below are what was administered in those specific models — not recommendations for human use.

TB-500 arm (full-length thymosin beta-4): topical application and intraperitoneal injection in rat wound models. As little as 10 picograms per treatment site stimulated keratinocyte migration in cell assays; the rat wound studies used topical preparations and IP injection at research concentrations ^[1]. The TB-500 fragment may behave differently from the full-length protein at equivalent mass doses.

BPC-157 arm: 10 micrograms, 10 nanograms, and 10 picograms per rat (intraperitoneal, once daily) in the Achilles tendon transection model — all three dose levels showed significant improvement versus untreated controls ^[2]. The first-in-human IV pilot used 10 mg on day 1 and 20 mg on day 2 in two adults (in 250 cc saline, 1-hour infusion) ^[6].

GHK-Cu arm: nanomolar concentrations in cell-culture studies; topical formulations in clinical cosmetic trials. The 2015 review reports active concentrations in the range of 1-10 nM for transcriptomic effects in fibroblasts ^[4].

KPV arm: 10 nM in cell culture for NF-kappaB inhibition assays; 100 micromolar in drinking water in murine colitis models. PepT1 substrate Km approximately 160 micromolar ^[3].

KLOW peptide dosage and frequency: the pharmacokinetic mismatch

The four peptides in KLOW have markedly different elimination half-lives — and this difference has direct implications for interpreting any dose schedule.

Molecular-weight gradient: the two tripeptides — KPV (342.44 Da) and GHK-Cu (402.92 Da) — are small enough to be filtered, metabolized, and cleared substantially faster than BPC-157 (1419.53 Da). BPC-157 has a short half-life in formal pharmacokinetic study (under approximately 30 minutes in plasma) ^[10], but it is longer-lived than the tripeptides, whose clearance has not been formally characterized for the blend setting.

TB-500 fragment vs. native thymosin beta-4: the fragment (889.02 Da) likely behaves pharmacokinetically differently from the 43-amino-acid native protein from which most wound-healing PK data derive.

The practical consequence: a single reconstituted vial, administered at one time point, cannot maintain all four components at matched tissue exposures simultaneously. By the time BPC-157 has distributed to its relevant tissue targets, the tripeptides may already be substantially cleared. This is a structural limitation of any co-formulated blend with components of such different molecular weights — not a criticism of the individual peptides, but an honest architectural constraint that dose-schedule assumptions must account for ^[10].

No human dosing study has examined KLOW peptide dosage and frequency in any species. No animal combination study has optimized a dose schedule.

Routes studied in component literature

Across the single-component research, multiple administration routes appear. The component literature covers:

• Subcutaneous injection — the primary route in research-handling contexts for most components
• Intraperitoneal injection — rodent model standard for BPC-157 and thymosin beta-4 / TB-500
• Topical application — GHK-Cu (extensive cosmetic and wound-healing data); thymosin beta-4 (wound studies) ^[1][4]
• Oral / targeted delivery — KPV via drinking water in murine colitis models, with PepT1-mediated gut uptake ^[3]; BPC-157 has gastric-cytoprotective data via oral route in rodents
• Intra-articular injection — BPC-157 in the retrospective knee-pain case series ^[8]
• Intravenous infusion — BPC-157 in the 2025 IV safety pilot ^[6]

No route has been validated for the full four-peptide blend in any controlled study.